How has Neuronetics ROCE changed compared to the previous year?

Return on Capital Employed (ROCE) of Neuronetics changed from -1.1 to -1.4 , representing a 27.35% change. The value is lower than the previous year.

How has Neuronetics ROCE developed historically?

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Neuronetics since 2006 – with annual values, charts, and detailed analysis.

What is the Neuronetics ROCE?

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Neuronetics with sector peers and the industry average to assess whether it is attractive.

How does Neuronetics ROCE compare to the industry average?

To evaluate Return on Capital Employed (ROCE)'s , it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Neuronetics ROCE

STIM

The Return on Capital Employed (ROCE) of Neuronetics (STIM) as of Jun 23, 2026 is -1.4.In the previous year, Return on Capital Employed (ROCE) was -1.1 — a change of 27.35% (lower).

Get this data via API

Financial Data API

ROCE

-1.4

YoY

27.35%

Last updated: Jun 23, 2026

In 2026, Neuronetics's return on capital employed (ROCE) was -1.4, a 27.35% increase from the -1.1 ROCE in the previous year.

Access this data via the Eulerpool API

Docs Get Free API Key

Neuronetics Stock analysis

What does Neuronetics do? Neuronetics Inc is a globally leading company in the field of non-invasive neuromodulatory technology. It was founded in 2003 and is headquartered in Malvern, Pennsylvania. The company specializes in the development and production of transcranial magnetic stimulation devices that can be used in the treatment of psychiatric disorders, particularly severe depression. Neuronetics' business model is based on selling its patented technology, called NeuroStar Advanced Therapy, to medical facilities worldwide. The company works closely with leading psychiatrists and clinical neurophysiologists to ensure that their devices meet the highest quality standards and can provide the best possible help to patients. The company has achieved a number of significant milestones in recent years. For example, in 2008, it received the first FDA approval for its technology. Since then, Neuronetics has continuously developed and improved its technology and has also obtained approvals in Europe and other parts of the world. Neuronetics is divided into various divisions, including research and development, manufacturing, and sales. Each of these departments is focused on ensuring the highest quality standards and ensuring that the technology of NeuroStar Advanced Therapy meets the needs of patients and medical personnel. The technology of NeuroStar Advanced Therapy is based on transcranial magnetic stimulation (TMS), which uses gentle magnetic fields to stimulate the activity of certain brain regions. The stimulation can help restore the balance of neurotransmitters in the brain and thus alleviate depression. Treatment with NeuroStar Advanced Therapy has significant advantages over conventional antidepressant medications. In many cases, it leads to faster improvement of symptoms and does not cause any of the undesirable side effects that can occur with medication. Overall, Neuronetics has developed a revolutionary technology with NeuroStar Advanced Therapy that can help millions of people around the world overcome their depression. The company is proud to contribute to improving the quality of life for people and will continue to develop innovative solutions in the field of neuromodulatory technology in the future. Neuronetics is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Neuronetics's Return on Capital Employed (ROCE)

Neuronetics's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Neuronetics's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Neuronetics's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Neuronetics’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Neuronetics ROCE

Neuronetics Stock analysis

ROCE Details

Unraveling Neuronetics's Return on Capital Employed (ROCE)

Year-to-Year Comparison

Impact on Investments

Interpreting ROCE Fluctuations

Frequently Asked Questions about Neuronetics stock

What is the Neuronetics ROCE 2026?

How has Neuronetics ROCE changed compared to the previous year?

How has Neuronetics ROCE developed historically?

What is the Neuronetics ROCE?

What is a good ROCE?

How does Neuronetics ROCE compare to the industry average?

Profitability — Neuronetics

All Key Metrics — Neuronetics

Valuation

Income Statement

Margins

Balance Sheet

Cash Flow

Profitability

Leverage

Growth

Dividend

Workforce

Quality

Other